Roivant subsidiary Dermavant acquired by Organon; merger closed Oct 28, 2024

Roivant Sciences Ltd.

Organon completed acquisition of Dermavant from Roivant on October 28, 2024, expanding dermatology portfolio.
VTAMA (tapinarof) cream 1% is FDA-approved for plaque psoriasis; sNDA for atopic dermatitis under review with PDUFA in Q4 2024.
Dermavant's credit agreement terminated upon closing; all amounts outstanding repaid.
Roivant President cites win-win outcome; expects to share meaningfully in VTAMA's success via collaboration.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.